Literature DB >> 12588207

Clinical and epidemiologic features of group a streptococcal pneumonia in Ontario, Canada.

Matthew P Muller1, Donald E Low, Karen A Green, Andrew E Simor, Mark Loeb, Daniel Gregson, Allison McGeer.   

Abstract

BACKGROUND: Since the 1960s, group A streptococcus (GAS) has accounted for less than 1% of cases of community-acquired pneumonia. During the past 2 decades there has been a resurgence of invasive GAS infection, but no large study of GAS pneumonia has been performed.
METHODS: To determine the clinical and epidemiologic features of GAS pneumonia, we conducted prospective, population-based surveillance of all invasive GAS infection in residents of Ontario from January 1, 1992, through December 31, 1999.
RESULTS: Of 2079 cases of invasive GAS infection, 222 (11%) represented GAS pneumonia. The incidence of GAS pneumonia ranged from 0.16 per 100 000 in 1992 to 0.35 per 100 000 in 1999. Most cases were community acquired (81%). Forty-four percent of nursing home-acquired cases occurred during outbreaks. The case fatality rate was 38% for GAS pneumonia, compared with 12% for the entire cohort with invasive GAS infection and 26% for patients with necrotizing fasciitis. The presence of streptococcal toxic shock syndrome (odds ratio, 19; 95% confidence interval, 8.4-42; P =.001) and increasing age (odds ratio per decade, 1.45; 95% confidence interval, 1.2-1.7; P<.001) were associated with fatal outcome. Time to death was rapid, with a median of 2 days despite antimicrobial therapy and supportive measures.
CONCLUSIONS: Group A streptococcal pneumonia is a common form of invasive GAS disease but remains an uncommon cause of community-acquired pneumonia. Progression is rapid despite appropriate therapy. The incidence is similar to, and the case fatality rate higher than, that of necrotizing fasciitis.

Entities:  

Mesh:

Year:  2003        PMID: 12588207     DOI: 10.1001/archinte.163.4.467

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  21 in total

1.  Severe skin and soft tissue infections and associated critical illness.

Authors:  Donald C Vinh; John M Embil
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

2.  Genetic diversity among type emm28 group A Streptococcus strains causing invasive infections and pharyngitis.

Authors:  Nicole M Green; Stephen B Beres; Edward A Graviss; James E Allison; Allison J McGeer; Jaana Vuopio-Varkila; Rance B LeFebvre; James M Musser
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

Review 3.  The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.

Authors:  Amber M Smith; Victor C Huber
Journal:  Viral Immunol       Date:  2017-11-17       Impact factor: 2.257

4.  Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections.

Authors:  Michael S Chaussee; Heather R Sandbulte; Margaret J Schuneman; Frank P Depaula; Leslie A Addengast; Evelyn H Schlenker; Victor C Huber
Journal:  Vaccine       Date:  2011-04-08       Impact factor: 3.641

5.  Binding host proteins to the M protein contributes to the mortality associated with influenza-Streptococcus pyogenes superinfections.

Authors:  Andrea L Herrera; Kuta Suso; Stephanie Allison; Abby Simon; Evelyn Schlenker; Victor C Huber; Michael S Chaussee
Journal:  Microbiology       Date:  2017-10       Impact factor: 2.777

6.  Simultaneous detection of pathogens in clinical samples from patients with community-acquired pneumonia by real-time PCR with pathogen-specific molecular beacon probes.

Authors:  Miyuki Morozumi; Eiichi Nakayama; Satoshi Iwata; Yasuko Aoki; Keiko Hasegawa; Reiko Kobayashi; Naoko Chiba; Takeshi Tajima; Kimiko Ubukata
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

7.  Genome-wide molecular dissection of serotype M3 group A Streptococcus strains causing two epidemics of invasive infections.

Authors:  Stephen B Beres; Gail L Sylva; Daniel E Sturdevant; Chanel N Granville; Mengyao Liu; Stacy M Ricklefs; Adeline R Whitney; Larye D Parkins; Nancy P Hoe; Gerald J Adams; Donald E Low; Frank R DeLeo; Allison McGeer; James M Musser
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-28       Impact factor: 11.205

8.  Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.

Authors:  Joshua M Klonoski; Heather R Hurtig; Brian A Juber; Margaret J Schuneman; Thomas E Bickett; Joshua M Svendsen; Brandon Burum; Thomas A Penfound; Grigoriy Sereda; James B Dale; Michael S Chaussee; Victor C Huber
Journal:  Vaccine       Date:  2014-07-29       Impact factor: 3.641

9.  Epidemiological features of invasive and noninvasive group A streptococcal disease in the Netherlands, 1992-1996.

Authors:  B Vlaminckx; W van Pelt; L Schouls; A van Silfhout; C Elzenaar; E Mascini; J Verhoef; J Schellekens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-05-26       Impact factor: 3.267

10.  Invasive group A streptococcal infection in older adults in long-term care facilities and the community, United States, 1998-2003.

Authors:  Michael C Thigpen; Chesley L Richards; Ruth Lynfield; Nancy L Barrett; Lee H Harrison; Kathryn E Arnold; Arthur Reingold; Nancy M Bennett; Allen S Craig; Ken Gershman; Paul R Cieslak; Paige Lewis; Carolyn M Greene; Bernard Beall; Chris A Van Beneden
Journal:  Emerg Infect Dis       Date:  2007-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.